tiprankstipranks
Dyadic International Strikes Major Biotech Deal with Proliant
Company Announcements

Dyadic International Strikes Major Biotech Deal with Proliant

Don't Miss our Black Friday Offers:

An update from Dyadic International (DYAI) is now available.

Dyadic International has inked a lucrative deal with Proliant Health and Biologicals, granting Proliant the rights to utilize Dyadic’s cutting-edge fungal production technology for creating recombinant serum albumin. This partnership will not only provide Dyadic with an immediate $500,000 upfront but also promises additional payments upon the achievement of key development milestones and a portion of the profits from product sales. This strategic move signifies a promising leap forward for both companies in the biotech industry.

See more data about DYAI stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyDyadic International receives $3M grant to develop antibodies for RSV, malaria
TipRanks Auto-Generated NewsdeskDyadic International Reports Q3 2024 Growth and Strategic Advances
TipRanks Auto-Generated NewsdeskDyadic International Aligns CFO Incentives with Performance
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App